HCPCS Level II code J7209 represents an injectable recombinant factor VIII product (Nuwiq) billed per 1 international unit. This code is used to document administration or provision of a biologic replacement therapy for patients with hemophilia A and is relevant across inpatient outpatient infusion and ambulatory care settings. Nationally, accurate use of J7209 affects medical billing, drug utilization tracking, and coverage determinations for high-cost specialty therapies.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context and common sites of service, typical payer coverage considerations, and billing elements associated with a unit-based biologic drug code. The publication also summarizes common modifiers seen in practice, although specific modifier application varies by payer policy.

This summary provides benchmarks for typical billing practice, highlights payer policy themes relevant to high-cost injectable biologics, and outlines where policy updates or coding clarifications may affect claims processing. Data not available in the input is noted where applicable, and the content focuses on national policy and clinical context rather than state-specific rules.